NasdaqGM:AUPHBiotechs
Aurinia (AUPH) Expands Autoimmune Pipeline With Zetomipzomib – Is Its Dependence On Lupkynis Fading?
Aurinia Pharmaceuticals recently highlighted progress in broadening its autoimmune portfolio, advancing aritinercept in clinical development and integrating Kezar Life Sciences’ zetomipzomib program following its acquisition.
This move shifts Aurinia’s story from dependence on Lupkynis alone toward a more diversified pipeline that could reshape its long-term autoimmune footprint.
We’ll now consider how this broadened autoimmune pipeline, particularly the addition of zetomipzomib, may...